Acusphere Future Up In Air After Imagify Fails Before Advisory Panel
Executive Summary
Evolving trial design standards and miscommunication with the review division tripped up Acusphere's effort to bring Imagify to market, signaling to competitors in the space that FDA is raising the bar on contrast imaging agents